Hazard Information | Back Directory | [Uses]
(S)-CE-123 is a potent, selective, and novel atypical dopamine transporter (DAT) inhibitor with an EC50 of 2.76 μM in uptake inhibition assays conducted in HEK293 cells stably expressing human isoforms of DAT. (S)-CE-123, a Modafinil analogue, is able to penetrate the blood–brain barrier. (S)-CE-123 improves cognitive and motivational processes in experimental animals[1][2]. | [in vivo]
(S)-CE-123 (6.0, 12.0, 24.0 mg/kg; ip; 30 min before testing) significantly attenuates the effects of TBZ (Tetrabenazine; HY-B0590) on lever pressing and chow intake. (S)-CE-123 alone has no significant difference with vehicle-treated rats[1].
Animal Model: | Trained rats (adult male Sprague-Dawley rats)[1] | Dosage: | 6.0, 12.0, 24.0 mg/kg | Administration: | IP; 30 min before testing | Result: | Attenuated the effects of TBZ (1.0 mg/kg) on lever pressing and chow intake.
|
| [References]
[1] Renee A Rotolo, et al. The Novel Atypical Dopamine Uptake Inhibitor (S)-CE-123 Partially Reverses the Effort-Related Effects of the Dopamine Depleting Agent Tetrabenazine and Increases Progressive Ratio Responding. Front Pharmacol. 2019 Jun 28:10:682. DOI:10.3389/fphar.2019.00682 [2] Eduardo R. Perez Gonzalez, et al. Process Development and Scale-Up of a Novel Atypical DAT Inhibitor (S)-CE-123. ACS Omega 2024, March 4. |
|
|